Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IMCD N.V. (IMCD.AS)
Rotterdam, NL
Founded in Rotterdam, the Netherlands, in 1995, IMCD N.V. operates as a leading global distributor and marketer of a diverse range of specialized chemicals and premium ingredients. Its extensive operations span across the Netherlands, the wider European continent, the Middle East, Africa, both North and South America, and the Asia-Pacific region. IMCD's comprehensive product portfolio serves numerous industries. For the pharmaceutical, agrochemical, and nutraceutical sectors, it provides essential active ingredients, excipients, formulation components, and compounds for regulated synthesis. Within personal care and cosmetics, the company supplies a wide array of offerings including active substances, UV filters, rheology modifiers, thickeners, emulsifiers, emollients, colorants, fragrances, and various functional additives for skin and hair products. Industrial applications benefit from resins, binders, functional fillers, and specialized solvents. Additionally, IMCD offers solutions for the food and beverage industry, focusing on enhancing taste, improving texture, and boosting nutritional value. The company also supports the energy sector with base oils, fuel and lubricant additives, and related fluids, alongside a broad spectrum of bio-based chemicals, catalysts, intermediates, and organic building blocks for various chemical processes.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14% | -0.94% | +5.44% | +5.37% | +17.99% | +25.32% | -22.06% | -31.09% | -22.12% | +174.56% | +333.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 6 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+1.1% Q4'25: +6.9% (vs Q4'23)
-
EPS growth Chemicals - Specialty: +13.2%-24.3% Q4'25: -39.2% (vs Q4'23)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+6.0% Q4'25: +9.0% (vs Q4'23)
-
EBIT margin Chemicals - Specialty: +8.8%+7.8% Q4'25: +6.6% (vs Q4'23)
-
ROIC Chemicals - Specialty: +5.6%+7.9% ★ Q4'25: +13.1% (vs Q4'23)
-
Share dilution Chemicals - Specialty: +0.1%+3.4% Q4'25: +3.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×3.31× Q4'25: 1.89× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 12 Rev. Ana. 9 EPS Ana. |
Dec 2028 9 Rev. Ana. 5 EPS Ana. |
Dec 2029 4 Rev. Ana. 1 EPS Ana. |
Dec 2030 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.36B
est: 1.39B (-2.2%)
|
1.53B
est: 1.54B (-0.6%)
|
1.71B
est: 1.72B (-0.3%)
|
1.91B
est: 1.90B (+0.3%)
|
2.38B
est: 2.39B (-0.6%)
|
2.69B
est: 2.69B (0.0%)
|
2.77B
est: 2.73B (+1.7%)
|
3.44B
est: 3.38B (+1.8%)
|
4.60B
est: 4.61B (-0.2%)
|
4.44B
est: 4.56B (-2.6%)
|
4.73B
est: 4.75B (-0.5%)
|
4.78B
est: 4.82B (-0.9%)
|
5.05B
4.94B – 5.15B
+4.6% YoY
|
5.25B
4.99B – 5.62B
+4.1% YoY
|
5.54B
5.53B – 5.54B
+5.4% YoY
|
5.63B
5.43B – 5.89B
+1.7% YoY
|
6.32B
6.10B – 6.61B
+12.3% YoY
|
| EBITDA |
112.89M
est: 162.49M (-30.5%)
|
127.06M
est: -10.44M (+1,316.6%)
|
143.56M
est: 116.30M (+23.4%)
|
165.86M
est: 137.42M (+20.7%)
|
207.11M
est: 167.20M (+23.9%)
|
239.18M
est: 185.09M (+29.2%)
|
258.23M
est: 188.13M (+37.3%)
|
394.79M
est: 208.26M (+89.6%)
|
574.63M
est: 217.41M (+164.3%)
|
566.90M
est: 546.76M (+3.7%)
|
589.14M
est: 571.22M (+3.1%)
|
514.17M
est: 578.59M (-11.1%)
|
605.05M
592.47M – 617.82M
+4.6% YoY
|
629.87M
599.01M – 674.12M
+4.1% YoY
|
664.08M
663.67M – 664.50M
+5.4% YoY
|
675.30M
651.57M – 706.42M
+1.7% YoY
|
758.19M
731.55M – 793.13M
+12.3% YoY
|
| EBIT |
80.00M
est: 125.77M (-36.4%)
|
88.81M
est: 92.31M (-3.8%)
|
115.36M
est: 103.05M (+11.9%)
|
123.61M
est: 118.56M (+4.3%)
|
162.89M
est: 156.64M (+4.0%)
|
173.73M
est: 178.77M (-2.8%)
|
185.46M
est: 174.88M (+6.1%)
|
302.36M
est: 193.59M (+56.2%)
|
463.47M
est: 202.10M (+129.3%)
|
453.08M
est: 422.96M (+7.1%)
|
452.53M
est: 441.88M (+2.4%)
|
371.25M
est: 447.58M (-17.1%)
|
468.05M
458.31M – 477.92M
+4.6% YoY
|
487.25M
463.37M – 521.47M
+4.1% YoY
|
513.71M
513.39M – 514.03M
+5.4% YoY
|
522.39M
504.03M – 546.46M
+1.7% YoY
|
586.51M
565.90M – 613.54M
+12.3% YoY
|
| Net Income |
19.91M
est: 68.52M (-70.9%)
|
61.85M
est: 22.32M (+177.2%)
|
72.96M
est: 69.88M (+4.4%)
|
77.26M
est: 80.46M (-4.0%)
|
100.06M
est: 96.69M (+3.5%)
|
108.01M
est: 113.24M (-4.6%)
|
120.13M
est: 107.28M (+12.0%)
|
207.28M
est: 118.76M (+74.5%)
|
313.08M
est: 288.73M (+8.4%)
|
292.27M
est: 280.84M (+4.1%)
|
278.24M
est: 346.44M (-19.7%)
|
217.58M
est: 311.90M (-30.2%)
|
322.76M
287.45M – 358.07M
+3.5% YoY
|
340.43M
306.66M – 374.19M
+5.5% YoY
|
393.38M
340.29M – 446.47M
+15.6% YoY
|
431.01M
411.33M – 456.83M
+9.6% YoY
|
486.00M
463.80M – 515.11M
+12.8% YoY
|
| SGA |
65.20M
est: 54.91M (+18.7%)
|
65.15M
est: 128.15M (-49.2%)
|
68.45M
est: 153.14M (-55.3%)
|
74.66M
est: 171.61M (-56.5%)
|
95.45M
est: 228.23M (-58.2%)
|
106.51M
est: 262.16M (-59.4%)
|
113.37M
est: 242.21M (-53.2%)
|
148.98M
est: 268.12M (-44.4%)
|
199.27M
est: 279.91M (-28.8%)
|
152.71M
est: 167.27M (-8.7%)
|
169.29M
est: 174.75M (-3.1%)
|
127.03M
est: 177.00M (-28.2%)
|
185.10M
181.25M – 189.00M
+4.6% YoY
|
192.69M
183.25M – 206.23M
+4.1% YoY
|
203.16M
203.03M – 203.28M
+5.4% YoY
|
206.59M
199.33M – 216.11M
+1.7% YoY
|
231.95M
223.80M – 242.64M
+12.3% YoY
|
| EPS |
0.79
est: 1.20 (-34.0%)
|
1.20
est: 1.67 (-28.1%)
|
1.39
est: 1.91 (-27.0%)
|
1.47
est: 2.09 (-29.7%)
|
1.91
est: 2.54 (-24.7%)
|
2.06
est: 2.64 (-22.0%)
|
2.24
est: 2.90 (-22.8%)
|
3.64
est: 4.52 (-19.5%)
|
5.50
est: 6.68 (-17.7%)
|
5.13
est: 4.93 (+4.0%)
|
4.86
est: 5.82 (-16.5%)
|
3.68
est: 5.14 (-28.4%)
|
5.34
4.86 – 6.06
+3.9% YoY
|
5.81
5.19 – 6.33
+8.8% YoY
|
6.32
5.76 – 7.55
+8.9% YoY
|
7.29
6.96 – 7.73
+15.3% YoY
|
8.22
7.84 – 8.71
+12.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marcus Jordan | Chief Executive Officer & Member of Management Board | 1M | male |
| Hans J. J. Kooijmans | Chief Financial Officer & Member of Management Board | 1M | male |
| Cecile Westerhuis | Company Secretary | — | female |
| Laurens Dalmijin | General Counsel | — | — |
| Muriel Werlé | Corporate Communications Director | — | female |
| Narendra Varde | Regional President Asia-Pacific | — | male |
| Swapna Kattewar | Head of Global Regulatory Questionnaire Centre | — | female |
| Andreas Igerl | Chief Commercial Officer & Member of Management Board | — | male |
| Tosca Holtland | Head of Investor Relations | — | female |
| Arturo Hoyo | Managing Director of IMCD Mexico | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMCD.AS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
